PURPOSE: In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel administration. In this article, we investigate the relationship between baseline serum androgen (SA) levels and OS. PATIENTS AND METHODS: COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5 mg by mouth twice daily; n = 797) versus P alone (n = 398). Randomization was stratified by Eastern Cooperative Oncology Group performance status (0 to 1 v 2), pain (Brief Pain Inventory-Short Form over past 24 hours: 4 to 10, present; v 0 to 3, absent), prior chemotherapy (1 v 2), and progression (prostate-specific antigen v radiographic). Association of baseline SA (testosterone, androstenedione, dehydroepiandrosterone sulfate), was measured by ultrasensitive liquid-liquid extraction or protein precipitation and two-dimensional liquid chromatography coupled to mass spectrometry, with OS determined by bivariate and multivariable Cox models. OS was examined with SA as greater than median and less than or equal to the median. RESULTS:Median survival increased with each quartile increase in testosterone level regardless of treatment arm. SA levels at baseline strongly associated with survival (P < .0001) in bivariate and multivariable analyses. Longer survival was observed for patients with SA above median compared with below median in both the AA and P arms (eg, testosterone, AA; hazard ratio, 0.64; 95% CI, 0.53 to 0.77; P < .0001). Treatment with AA led to longer survival versus P alone in the above- or below-median group for all androgens. CONCLUSION: SA, measured with a novel ultrasensitive assay in COU-AA-301, is prognostic for OS and may be useful for risk stratification in mCRPC clinical trials.
RCT Entities:
PURPOSE: In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel administration. In this article, we investigate the relationship between baseline serum androgen (SA) levels and OS. PATIENTS AND METHODS: COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5 mg by mouth twice daily; n = 797) versus P alone (n = 398). Randomization was stratified by Eastern Cooperative Oncology Group performance status (0 to 1 v 2), pain (Brief Pain Inventory-Short Form over past 24 hours: 4 to 10, present; v 0 to 3, absent), prior chemotherapy (1 v 2), and progression (prostate-specific antigen v radiographic). Association of baseline SA (testosterone, androstenedione, dehydroepiandrosterone sulfate), was measured by ultrasensitive liquid-liquid extraction or protein precipitation and two-dimensional liquid chromatography coupled to mass spectrometry, with OS determined by bivariate and multivariable Cox models. OS was examined with SA as greater than median and less than or equal to the median. RESULTS: Median survival increased with each quartile increase in testosterone level regardless of treatment arm. SA levels at baseline strongly associated with survival (P < .0001) in bivariate and multivariable analyses. Longer survival was observed for patients with SA above median compared with below median in both the AA and P arms (eg, testosterone, AA; hazard ratio, 0.64; 95% CI, 0.53 to 0.77; P < .0001). Treatment with AA led to longer survival versus P alone in the above- or below-median group for all androgens. CONCLUSION:SA, measured with a novel ultrasensitive assay in COU-AA-301, is prognostic for OS and may be useful for risk stratification in mCRPC clinical trials.
Authors: Charles J Ryan; Shreya Shah; Eleni Efstathiou; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Christopher J Logothetis; Thian Kheoh; Christine Kilian; Christopher M Haqq; Arturo Molina; Eric J Small Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: Charles J Ryan; Susan Halabi; San-San Ou; Nicholas J Vogelzang; Philip Kantoff; Eric J Small Journal: Clin Cancer Res Date: 2007-04-01 Impact factor: 12.531
Authors: Alison H M Reid; Gerhardt Attard; Daniel C Danila; Nikhil Babu Oommen; David Olmos; Peter C Fong; L Rhoda Molife; Joanne Hunt; Christina Messiou; Christopher Parker; David Dearnaley; Joost F Swennenhuis; Leon W M M Terstappen; Gloria Lee; Thian Kheoh; Arturo Molina; Charles J Ryan; Eric Small; Howard I Scher; Johann S de Bono Journal: J Clin Oncol Date: 2010-02-16 Impact factor: 44.544
Authors: Janet L Stanford; Elizabeth A Noonan; Lori Iwasaki; Suzanne Kolb; Robert B Chadwick; Ziding Feng; Elaine A Ostrander Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-03 Impact factor: 4.254
Authors: Robert W Ross; William K Oh; Wanling Xie; Mark Pomerantz; Mari Nakabayashi; Oliver Sartor; Mary-Ellen Taplin; Meredith M Regan; Philip W Kantoff; Matthew Freedman Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk Journal: Cancer Res Date: 2006-03-01 Impact factor: 12.701
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: K Miller; P Albers; R Eichenauer; G Geiges; M-O Grimm; F König; G Mickisch; D Pfister; C Schwentner; H Suttmann; S Zastrow Journal: Urologe A Date: 2016-09 Impact factor: 0.639
Authors: Xu Steven Xu; Charles J Ryan; Kim Stuyckens; Matthew R Smith; Fred Saad; Thomas W Griffin; Youn C Park; Margaret K Yu; Peter De Porre; An Vermeulen; Italo Poggesi; Partha Nandy Journal: Clin Pharmacokinet Date: 2017-01 Impact factor: 6.447
Authors: Charles J Ryan; Sandipan Dutta; William K Kelly; Rob Middleberg; Carly Russell; Michael J Morris; Mary-Ellen Taplin; Susan Halabi Journal: Clin Genitourin Cancer Date: 2019-10-17 Impact factor: 2.872
Authors: Won Kim; Li Zhang; John H Wilton; Gerald Fetterly; James L Mohler; Vivian Weinberg; Allison Morse; Russell Z Szmulewitz; Terence W Friedlander; Lawrence Fong; Amy M Lin; Andrea L Harzstark; Arturo Molina; Eric J Small; Charles J Ryan Journal: Clin Cancer Res Date: 2014-10-21 Impact factor: 12.531
Authors: Matteo Ferro; Daniela Terracciano; Carlo Buonerba; Giuseppe Lucarelli; Danilo Bottero; Sisto Perdonà; Riccardo Autorino; Alessandro Serino; Francesco Cantiello; Rocco Damiano; Iulia Andras; Sabino De Placido; Giuseppe Di Lorenzo; Michele Battaglia; Barbara A Jereczek-Fossa; Vincenzo Mirone; Ottavio De Cobelli Journal: Future Oncol Date: 2016-09-14 Impact factor: 3.404
Authors: R R McKay; L Werner; M Fiorillo; M Nakabayashi; P W Kantoff; M-E Taplin Journal: Prostate Cancer Prostatic Dis Date: 2016-08-09 Impact factor: 5.554